Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
4
Neutral
6
Bullish
4
Bearish
7
Neutral
6
Bullish
33
Bearish
3
Neutral
0
Bullish
29
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Upcoming Result Date: May 13, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Global Health Limited (Medanta) is a leading healthcare provider in India, operating multi-specialty tertiary care hospitals across key regions with specialties in cardiology, oncology, neurology, and more.
The company has expanded its operations significantly over the years, with recent additions including a new facility in Noida and substantial growth in its Lucknow and Patna hospitals.
Medanta reported a robust 19% year-on-year revenue growth in Q3 FY26, despite early-stage operational losses from its new Noida hospital, reflecting strong operational momentum across its network.
The company is making significant investments in cancer care, having launched a large-scale cancer awareness program and commissioning advanced radiation oncology machines to enhance treatment capacity.
Medanta's Lucknow facility recently achieved Joint Commission International (JCI) accreditation, underscoring its commitment to delivering high global standards of clinical quality and patient safety.
Healthcare Services
Hospital
32,278 Cr
Low Risk
62.8
59.2
1.9
8.7
1,455.85
955.20
Sales CAGR
Profit CAGR
ROE
ROCE
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Global Health Ltd (MEDANTA) is currently trading at 1,196.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Global Health Limited (Medanta) is a leading healthcare provider in India, operating multi-specialty tertiary care hospitals across key regions with specialties in cardiology, oncology, neurology, and more. The company has expanded its operations significantly over the years, with recent additions including a new facility in Noida and substantial growth in its Lucknow and Patna hospitals. Medanta reported a robust 19% year-on-year revenue growth in Q3 FY26, despite early-stage operational losses from its new Noida hospital, reflecting strong operational momentum across its network. The company is making significant investments in cancer care, having launched a large-scale cancer awareness program and commissioning advanced radiation oncology machines to enhance treatment capacity. Medanta's Lucknow facility recently achieved Joint Commission International (JCI) accreditation, underscoring its commitment to delivering high global standards of clinical quality and patient safety.
Over the past 52 weeks, Global Health Ltd has traded between a low of ₹955.20 and a high of ₹1,455.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Global Health Ltd has a market capitalization of approximately 32,278.36. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Global Health Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 62.81 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 32,278.36 Cr, Global Health Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Global Health Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Global Health Ltd is 62.81. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The plan to train one lakh Allied Health Professionals and the scheme to establish five regional medical tourism hubs are the most significant announcements, as they address key operational needs and growth drivers for Medanta.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
658.90 | 38,465 Cr | 99.10 | 9.10 | 0.40 | 8.48 | 10.10 | 5.27 | ||
1765.00 | 37,189 Cr | 47.74 | 9.16 | 0.25 | 20.82 | 17.75 | 10.07 | ||
1244.00 | 32,278 Cr | 62.81 | 8.71 | 0.00 | 15.15 | 16.83 | 9.50 | ||
680.00 | 28,712 Cr | 95.48 | 12.65 | 0.00 | 14.80 | 10.88 | 4.75 | ||
454.00 | 14,404 Cr | 114.27 | 7.46 | 0.00 | 5.94 | 9.26 | 4.25 | ||
1255.10 | 13,252 Cr | 51.44 | 8.73 | 0.23 | 16.72 | 17.60 | 10.05 | ||
195.70 | 10,779 Cr | 42.65 | 5.50 | 0.00 | 20.61 | 19.00 | 0.00 | ||
| Median: 7 Co. | — | 680.00 | 28,712 Cr | 62.81 | 8.73 | 0.00 | 15.15 | 16.83 | 5.27 |
Board Meeting - Results
Board scheduled for 14-May-2026 to consider and approve audited financial results for the quarter and year ended 31-Mar-2026 and to consider recommending a final dividend; trading window closed until 48 hrs after results.
Board Meeting Results
Global Health Limited has scheduled a Board meeting on 14-May-2026 to consider and approve audited financial results for the quarter and year ended 31-Mar-2026 and to consider/recommend a final dividend; trading window closed.
